medigraphic.com

2018, Number 2

<< Back Next >>

Anales de Radiología México 2018; 17 (2)

Staging and analysis of treatment response in patients with non Hodgkin’s lymphoma using whole body MRI with diffusion weighted images

Cortés-Chávez LC, Vega-Gutiérrez AE, Amezcua-Herrera MC, Montaño-Figueroa EH, Ramírez-López R, Guerrero-Avendaño G

Language: Spanish
References: 17
Page: 118-131
PDF size: 1153.63 Kb.


ABSTRACT

Introduction: Whole body diffusion-weighted MRI is a complement of anatomic MRI and provides a functional assessment of the disease and its quantification with no need of contrast; at long term there are few risks and it is performed in a reasonably short time.
Objective: Analyze staging and treatment response in patients with non Hodgkin´s lymphoma using whole body MRI with diffusion weighted images.
Material and Methods: Patients who had a baseline and interval MRI using whole body diffusion protocol were included, with available Ris-Pacs system archives at the Hospital General de México “Dr. Eduardo Liceaga”, performed from January 1st 2016 to June 30, 2017.
Results: Of the 10 patients who had whole body diffusion, only 8 were included, one was left out for not having measurable lesions, and a second patient for not having the interval study. The most common histology was Large Cell Lymphoma, the clinical stage with the greatest distribution was stage IV. Partial treatment response was found in 87.5%.
Conclusions: It is considered that MRI is a good method for proper staging and assessment of treatment response in patients with non Hodgkin´s Lymphoma, and possibly in all other cancers; this study is considered as a pilot project on the topic, raising interest in different medical fields.


REFERENCES

  1. Graessner J. Frequently asked questions: diffusion-weighted imaging (DWI). MAGNETOM Flash 1/2011.

  2. Padhani AR, Makris A, Gall P, Collins DJ, Tunariu N, de Bono JS. Therapy monitoring of skeletal metastases with whole-body diffusion MRI. J Magn Reson Imaging. 2014;39:1049-78 .

  3. Padhani AR, Douis H and Gall P. Whole-body diffusion-weighted MRI of the bone marrow in health and disease. Oncology Clinical MAGNETOM Flash. 2/2012. Disponible en: https://static.healthcare.siemens.com/siemens_ hwem-hwem_ssxa_websites-context-root/wcm/idc/groups/ public/@global/documents/download/mdaw/mjqw/~edisp/magnetom_ flash_50_rsna2012_final-00276521.pdf

  4. Takahara T, Imai Y, Yamashita T, Yasuda S, Nasu S, Van Cauteren M. Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med. 2004;22:275-82.

  5. Koh DM, Blackledge M, Padhani AR, Takahara T, Kwee TC, Leach MO, et al. Whole-body diffusion-weighted MRI: tips, tricks, and pitfalls. AJR Am J Roentgenol. 2012;199:252-62.

  6. Toledano-Massiah S, Luciani A, Itti E, Zerbib P, Vignaud A, Belhadj K, et al. Whole-body diffusion-weighted imaging in Hodgkin lymphoma and diffuse large B-cell lymphoma. Radiographics. 2015;35:747-64.

  7. Teixeira SR, Elias Junior J, Nogueira-Barbosa MH, Guimarães MD, Marchiori E, Santos MK. Whole-body MRI in pediatrics: state of the art. Radiol Bras. 2015;48:111-20.

  8. Lin C. Whole-body diffusion magnetic resonance imaging in the assessment of lymphoma. Cancer Imaging. 2012;12:403-8.

  9. Abdulqadhr G, Molin D, Aström G, Suurküla M, Johansson L, Hagberg H, et al. Whole-body diffusion-weighted imaging compared with FDG-PET/ CT in staging of lymphoma patients. Acta Radiol. 2011;52:173-80.

  10. Johnson SA, Kumar A, Matasar MJ, Schöder H, Rademaker J. Imaging for staging and response assessment in lymphoma. Radiology. 2015;276:323-38.

  11. van Ufford HM, Kwee TC, Beek FJ, van Leeuwen MS, Takahara T, Fijnheer R, et al. Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/CT. AJR Am J Roentgenol. 2011;196:662-9.

  12. Padhani AR, Koh DM, Collins DJ. Whole-body diffusion-weighted MR imaging in cancer: current status and research directions. Radiology. 2011;261:700-18.

  13. Campos-Hernández LD, Carrillo-Mezo R, Bourlon-Cuellar R, Sarré-Álvarez D, Sánchez-Cortázar J, Gómez-Pérez MG, Valor de la resonancia magnética y del protocolo de cuerpo completo en mieloma múltiple. Med Int Mex. 2014;30:745-54.

  14. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0. Incidencia de cáncer y mortalidad en todo el mundo: IARC Cancer Base No. 11. Lyon, Francia: Agencia Internacional para la Investigación del Cáncer; 2013. (Consultado en mayo de 2017.) Disponible en: http://globocan.iarc.fr/Pages/references.aspx

  15. Pearce MS, Salotti JA, Little MP, McHugh K, Lee C, Kim KP, et al. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. Lancet. 2012;380: .

  16. Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, et al. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol. 2017;28:1436-47.

  17. Candelaria M, Cervera-Ceballos E, Meneses-García A, Avilés-Salas A, Lome-Maldonado C, Zárate-Osorno A, et al. Guías nacionales de diagnóstico y tratamiento de linfoma no Hodgkin. Rev Invest Clin. 2013;65(Supl 2):S5-S26.




2020     |     www.medigraphic.com